Genocea Aims To Take The T-Cell Century By The Horns
Although cancer grabs the spotlight for harnessing the immune system against tumors, other therapeutic areas and modalities are being developed in the shadows. Genocea Biosciences thinks it has a surefire way to identify novel antigens for T-cell vaccines. It hopes to shake up large infectious disease markets, and more.
You may also be interested in...
Recent M&A activity in the vaccine industry has narrowed the pool of players. For companies that remain, the opportunity to reshape their positions in the global market comes with an even greater responsibility to contribute meaningfully to continued advances in global public health.
Vaccine consultant Jacqueline Keith in an interview described promising advances but also challenges to the funding, development, and delivery of vaccines to the neediest populations. The role of public/private partnerships at each stage of the vaccine value chain is critical to assuring win-win outcomes.
“While we have seen some decline in vaccine efficacy over time, the sheer number of children affected by malaria means that the number of cases of the disease the vaccine can help prevent is impressive,” GSK CEO Witty says.